Oncternal Therapeutics (NASDAQ:ONCT) Research Coverage Start

StockNews.com initiated coverage on shares of Oncternal Therapeutics (NASDAQ:ONCT – Free Report) in a research note released on Wednesday. The firm issued a hold rating on the stock. Separately, HC Wainwright dropped their target price on shares of Oncternal Therapeutics from $30.00 to $28.00 and set a buy rating on the stock in a report […]

Related Keywords

, Oncternal Therapeutics Company Profile , Richmond Brothers Inc , Pasadena Private Wealth , Renaissance Technologies , Millennium Management , Oncternal Therapeutics Inc , Vanguard Group Inc , Oncternal Therapeutics , Free Report , Get Free Report , Director Robert James Wills , Private Wealth , Orphan Receptor , Oncternal Therapeutics Daily , Nasdaq Onct , Conct , Medical , Initiated Coverage , Stocknews Com ,